ライフサイエンスコーパス: adenosine receptor antagonist

1 lfactory learning and memory by acting as an adenosine receptor antagonist.

2 p was blocked by theophylline, a nonspecific adenosine receptor antagonist.

3 ither saline or theophylline, a non-specific adenosine receptor antagonist.

4 by the PKA antagonist (R(p))-cAMPS and by an adenosine receptor antagonist.

5 eritoneal injection of 10 mg/kg caffeine, an adenosine receptor antagonist.

6 enyl theophylline (10(-5) M), a nonselective adenosine receptor antagonist.

7 sing ZM 241385, a potent and selective A(2A) adenosine receptor antagonist.

8 d, dopamine-deficient mice were treated with adenosine receptor antagonists.

9 were critical for the high affinity of A(3) adenosine receptor antagonists.

10 s constitute a novel class of selective A(3) adenosine receptor antagonists.

11 have been shown to be highly selective A(3) adenosine receptor antagonists.

12 glutamate (mGlu), GABAA, GABAB, glycine and adenosine receptor antagonists.

13 that treatment of obese Zucker rats with the adenosine receptor antagonist 1,3-dipropyl-8-(p-acrylic)

14 r administration of a nonselective A1 and A2 adenosine receptor antagonist 1,3-dipropyl-8-p-sulfophen

15 Two selective A1 adenosine receptor antagonists (10(-7) or 10(-5) M) had

16 tory activity is reversed by an A2 selective adenosine receptor antagonist 3,7-dimethyl-1-propargyl x

17 phorbol but was completely abolished by the adenosine receptor antagonist 8-(p-sulfophenyl)-theophyl

18 ating effects were entirely prevented by the adenosine receptor antagonist 8-(p-sulfophenyl)-theophyl

19 A were sensitive to the antagonism by the A1 adenosine receptor antagonist 8-cyclopentyl-1,3-dipropyl

20 ith vehicle (control) or the irreversible A1 adenosine receptor antagonist 8-cyclopentyl-3-[3-[[4-(fl

21 , EHNA, and PD81,723 were reversed by the A1 adenosine receptor antagonist 8-cyclopentyltheophylline

22 on of adenosine either with the nonselective adenosine receptor antagonist 8-p-sulfophenyl theophylli

23 locked by pretreatment with the nonselective adenosine receptor antagonist 8-p-sulfophenyl theophylli

24 phonic acid (PPADS; 100 microM), but not the adenosine receptor antagonist 8-phenyltheophylline (8-PT

25 for 5 min) before and after addition of the adenosine receptor antagonist 8-phenyltheophylline (8-PT

26 These responses were blocked by the adenosine receptor antagonist 8-phenyltheophylline (8-PT

27 In the other (n = 5), the nonspecific adenosine receptor antagonist 8-phenyltheophylline (8PT)

28 The non-selective adenosine receptor antagonist 8-SPT had no further effec

29 Subsequent administration of the adenosine receptor antagonist 8-sulphophenyl theophyllin

30 By contrast, the adenosine receptor antagonist 8-sulphophenyltheophylline

31 Topical application of the adenosine receptor antagonist 8-sulphophenyltheophylline

32 ever, in CHU rats, neither the non-selective adenosine receptor antagonist 8-sulphophenyltheopylline

33 boxamido)adenosine (NECA) and blocked by the adenosine receptor antagonist, 8-(p-sulfophenyl) theophy

34 by pretreatment not only with a non-specific adenosine receptor antagonist, 8-phenyltheophylline (8-P

35 Because the adenosine receptor antagonist 8PT attenuated this hypere

36 e-dimensional features responsible for A(2B) adenosine receptor antagonist activity.

37 (control) and combined L-NMMA-aminophylline (adenosine receptor antagonist) administration.

38 ngested psychoactive drug and a nonselective adenosine receptor antagonist, alters CB function and ve

39 ttent intratumor injection of a nonselective adenosine receptor antagonist, aminophylline (AMO; theop

40 ed mice; this effect is reversed with an A2A adenosine receptor antagonist and abolished in A2A recep

41 he effects could be antagonized by a charged adenosine receptor antagonist and by adenosine deaminase

42 Experiments using adenosine receptor antagonists and cells from A(2B)AR(-/

43 Because caffeine (a nonselective adenosine receptor antagonist) and selective adenosine A

44 It has been reported that A1 adenosine receptor antagonists are highly effective for

45 A(3) adenosine receptor antagonists are sought for their pote

46 kg, i.p.), a centrally active, non-selective adenosine receptor antagonist, attenuated the effects of

47 hophenyltheophylline (8-SPT; a non-selective adenosine receptor antagonist) before the fourth contrac

48 Pretest treatment with the adenosine receptor antagonist caffeine (7 mg/kg ip) reve

49 tive interaction between chronic exposure to adenosine receptor antagonist caffeine and genetic influ

50 Locomotor activity induced by the adenosine receptor antagonist caffeine was significantly

51 k and NBTI were reversed by the nonselective adenosine receptor antagonist caffeine, and the highly s

52 Acute administration of the nonselective adenosine receptor antagonist, caffeine (5-25 mgkg i.p.)

53 linical notion that caffeine, a nonselective adenosine receptor antagonist, can trigger or exacerbate

54 e (VUF8501, VUF8503, VUF8505), the classical adenosine receptor antagonist CGS15943 and the A(1) rece

55 This effect was prevented by a pan-adenosine receptor antagonist CGS15943, but not by A1 or

56 A mixture of the three adenosine receptor antagonists completely suppressed inh

57 The consumption of caffeine (an adenosine receptor antagonist) correlates inversely with

58 Caffeine (5, 10, or 15 mg/kg), a nonspecific adenosine receptor antagonist, dose-dependently and at h

59 The inhibition was abolished by the A(1) adenosine receptor antagonist DPCPX (8-cyclopentyl-1,3-d

60 In addition, because A1 adenosine receptor antagonist failed to block renal IPC,

61 In contrast, an adenosine receptor antagonist failed to prevent protecti

62 The adenosine receptor antagonist had a modest vasoconstrict

63 Finally, the application of adenosine receptor antagonists has been implicated in pr

64 appears to be an effective and selective A1 adenosine receptor antagonist in humans.

65 ith the synthesis of an A2-subtype selective adenosine receptor antagonist in only two steps.

66 Treatment with selective adenosine receptor antagonists indicated a contribution

67 r adenosine, and by aminophylline, a general adenosine receptor antagonist, indicating that they are

68 in models, oral intake of caffeine, a potent adenosine receptor antagonist, interferes with acupunctu

69 n attractive scaffold for the preparation of adenosine receptor antagonists, is the low water solubil

70 IA) and was reduced following treatment with adenosine receptor antagonist isobutylmethylxanthine (IB

71 A1 adenosine receptor antagonists may be useful for the pre

72 the food-, beverage-, and medication-derived adenosine receptor antagonists may modify an individual'

73 Adenosine receptor antagonists MRS1706 and DPCPX with kn

74 latory effect on migration was blocked by an adenosine receptor antagonist, MRS1754, ARL67156, an ect

75 or antagonist, or a selective A(2A) or A(2B) adenosine-receptor antagonist, negated the resistance to

76 ts to investigate the effect of selective A1 adenosine receptor antagonists on ischemia-reperfusion i

77 on was to examine the effect of caffeine (an adenosine receptor antagonist) on whole-body insulin-med

78 Studies with adenosine receptor antagonists or the adenosine uptake b

79 eophylline (SPT [50 mumol/L], a nonselective adenosine receptor antagonist), or calphostin C (100 nmo

80 tment with a CD73 antagonist, a nonselective adenosine-receptor antagonist, or a selective A(2A) or A

81 Prospective (anti-IgE therapy, adenosine receptor antagonists, phosphodiesterase inhibi

82 l/L 8-(p-sulfophenyl) theophylline (SPT), an adenosine receptor antagonist; preconditioned hearts als

83 ata and a general pharmacophore model for A3 adenosine receptor antagonists recently proposed, we app

84 We also show that treatment with an A1-adenosine receptor antagonist reduces the severity of lu

85 trolled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients H

86 trolled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients H

87 Controlled Randomized Study of the Selective Adenosine Receptor Antagonist Rolofylline for Patients H

88 after prolonged ischemia and reperfusion, A1 adenosine receptor antagonists should provide a protecti

89 A1 adenosine receptor antagonists significantly reduce isch

90 27.1 +/- 4.8% following the A(2A) selective adenosine receptor antagonist, similar to that observed

91 ot affected by administration of the general adenosine receptor antagonist theophylline and the A1 an

92 zyme therapy and also through the use of the adenosine receptor antagonist theophylline, implicating

93 4 mg/kg, per os) that are reversible with an adenosine receptor antagonist (theophylline).

94 The effects of 2 nonselective adenosine receptor antagonists, theophylline and caffein

95 transport small therapeutic amounts of an A1 adenosine receptor antagonist to the respiratory centers

96 restingly, the drug aminophylline, a general adenosine receptor antagonist used to block retinal wave

97 Three novel families of A2B adenosine receptor antagonists were identified in the co

98 while P2Y-selective receptor antagonists or adenosine receptor antagonists were ineffective.

99 enyl)-theophylline) (8-SPT), a non-selective adenosine receptor antagonist which has been found to be

100 y reduced by 8-phenyltheophylline (8-PT), an adenosine receptor antagonist which is non-selective bet

101 e reversed completely by two different A(2A) adenosine receptor antagonists without affecting T cells

102 However, the nonselective adenosine receptor antagonist xanthine amine congener co

103 The selective A1 adenosine receptor antagonists xanthine amine congener (

104 The selective A2A adenosine receptor antagonist ZM241385 (3 mg kg(-1), I.V